Ivabradine Accord

Ivabradine, the active ingredient in Ivabradine Accord, is a If channel inhibitor presented as an oral tablet for oral use. It is used to treat chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients who require heart‑rate reduction without affecting contractility.

GNH USA supplies Ivabradine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is indicated for conditions where heart‑rate reduction improves clinical outcomes. - Chronic stable angina pectoris: decreases the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and reduces hospitalisation risk. - Elevated resting heart rate in patients with coronary artery disease: helps control heart rate when beta‑blockers are insufficient or not tolerated.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Bradycardia: heart rate below the therapeutic range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Symptomatic heart block. - Persistent visual impairment. - Allergic reactions including rash or angioedema.

Before initiating ivabradine, clinicians should consider several safety measures. - Baseline heart‑rate monitoring: ensure resting heart rate is ≥60 bpm before starting. - Severe hypotension: avoid use in patients with systolic BP <90 mmHg. - Sick sinus syndrome or AV block: contraindicated unless a pacemaker is present. - Hepatic impairment: dose adjustment may be required. - Pregnancy category B: use only if potential benefit justifies the risk. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Ivabradine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce ivabradine exposure. - Concurrent bradycardic agents (beta‑blockers, digoxin, verapamil, diltiazem): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise ivabradine concentrations. - Antacids containing aluminum or magnesium: can affect oral absorption; separate administration by at least 2 hours. - Alcohol: may potentiate bradycardic effects and should be used cautiously.